Latest Articles
Relugolix in Monotherapy and Combined Therapy for the Treatment of Uterine Diseases and Its Effects on Bones: A Systematic Review.
Background: Uterine fibroids (UFs) and endometriosis are gynecological conditions that significantly increase morbidity among women of reproductive age. Relugolix, a novel gonadotropin-releasing hormone receptor antagonist, is approved in combined therapy …
Published: July 30, 2025, midnight
Relugolix Combination Therapy Improves Pain, Functioning, and Quality of Life in Women with... - Medical Dialogues
Relugolix Combination Therapy Improves Pain, Functioning, and Quality of Life in Women with... Medical Dialogues
Published: Nov. 11, 2024, 3:45 p.m.
Relugolix Combination Therapy Improves Pain, Functioning, and Quality of Life in Women with Endometriosis: Study - Medical Dialogues
Relugolix Combination Therapy Improves Pain, Functioning, and Quality of Life in Women with Endometriosis: Study Medical Dialogues
Published: Nov. 11, 2024, 3:45 p.m.
A Podcast on Patient and Physician Perspectives on the Management of Endometriosis and Relugolix Combination Therapy.
Endometriosis is a common disease, affecting approximately 5-10% of reproductively aged women. Symptoms, such as painful periods, negatively impact an individual's quality of life; however, these symptoms are often normalized, …
Published: Oct. 19, 2024, midnight
Once Daily Oral Relugolix Combination Therapy Versus Placebo in Patients With Endometriosis-Associated Pain: Two Replicate Phase 3, Randomised, Double-Blind, Studies (SPIRIT 1 and 2).
The author describes the results of a study to examine the effect of three treatment regimens on pain associated with endometriosis.
Published: Oct. 9, 2024, midnight
Relugolix combination therapy effective, safe for premenopausal women with endometriosis - Healio
Relugolix combination therapy effective, safe for premenopausal women with endometriosis Healio
Published: June 11, 2024, 7 a.m.
Link copied to clipboard!